Press Releases 2seventy bio, Inc.

Equities

TSVT

US9013841070

Real-time Estimate Cboe BZX Other stock markets 03:11:34 2024-04-29 pm EDT			5-day change	1st Jan Change
4.545 ^USD	+6.82%		-2.58%	+6.09%

Apr. 19	US FDA mandates label updates on CAR-T cancer therapies	RE
Apr. 05	Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA Approves BMS And J&J CAR-T Cell Therapies For The Earlier Treatment Of Multiple Myeloma	Apr. 17	AQ
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma after Two Prior Lines of Therapy	Apr. 08	AQ
2seventy bio : Corporate Presentation April 2024	Apr. 01	PU
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron	Apr. 01	BU
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors	Mar. 20	BU
Thinking about buying stock in Solidion Technology, Nuvei, 2Seventy Bio, Aeye, or DHC Acquisition?	Mar. 18	PR
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy	Mar. 18	AQ
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress	Mar. 05	BU
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences	Mar. 04	AQ
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences	Mar. 01	BU
2seventy bio to Participate in Upcoming Investor Conferences	Feb. 05	BU
2seventy bio Announces New Strategic Path Forward	Jan. 30	BU
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)	Dec. 11	BU
2seventy bio Reiterates Commitment to Maximizing Shareholder Value	Dec. 06	BU
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma	Nov. 21	AQ
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress	Nov. 14	BU
2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023	Nov. 10	BU
2seventy bio : Results of Operations and Financial Condition - Form 8-K	23-10-26	PU
2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway	23-09-12	BU
2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies	23-09-12	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases 2seventy bio, Inc.

Equities

TSVT

US9013841070

Press Releases

Filters